First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02 from Genzada Pharmaceuticals

Genzada Pharmaceuticals USA Inc. announced today that the first patient enrolled in its Phase 1 clinical trial for the oral therapeutic GZ17-6.02 received the first dose this week at HonorHealth Research Institute in Scottsdale, Ariz.

The release as fetched from its publisher. genzada.com ↗